comprehensive -WSS

comprehensive

author：fashion 2025-10-01 11:45:47 - browse：4246

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Virtual care provider acquires bankrupt Pear's prescription apps

WSS

Johnson & Johnson sues to stop Medicare negotiation

Johnson & Johnson sues to stop Medicare negotiation

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

Flagship, Pfizer team up in deal worth up to $7 billion

Biden administration sends mixed signals on US soldier who crossed into North Korea

Carvykti CAR

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

In Memoriam: Notable people who died in 2023

What we know about the American soldier detained in North Korea

The cancer drug shortage isn’t new — and neither are the solutions

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Hepatitis C has a cure — but many Americans still lack access to it

Christmas in the PICU brings some surprising joy

Affirmative action in medical school literally saved lives

Biden administration sends mixed signals on US soldier who crossed into North Korea

At least 13 dead in Texas as scorching temps continue

Virtual care provider acquires bankrupt Pear's prescription apps

leisure time

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

Why health records don't always know when patients are dead

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

Biden administration sends mixed signals on US soldier who crossed into North Korea

Study: Hearing aids may slow cognitive decline in those at risk

Christmas in the PICU brings some surprising joy

hotspot

focus

entertainment

hotspot